BioCentury
ARTICLE | Clinical News

Emricasan: Ph IIb started

November 18, 2016 6:21 PM UTC

Conatus began the double-blind, placebo-controlled, international Phase IIb ENCORE-PH trial to evaluate 5, 25 and 50 mg oral emricasan twice daily for 24 weeks in about 240 patients with compensated o...

BCIQ Company Profiles

Conatus Pharmaceuticals Inc.

BCIQ Target Profiles

Caspases